60 Degrees Pharmaceuticals to Sponsor Pilot Study of
60 Degrees Pharma (Nasdaq: SXTP) will sponsor a study using tafenoquine, an FDA-approved malaria drug, to treat canine babesiosis, a tick-borne disease....
Source: globenewswire.com
Patrick Gaynes News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Patrick Gaynes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Patrick Gaynes Today - Breaking & Trending Today
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatmentMonash University will conduct the studies beginning in second quarter of 2024 WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ: SXTP; SXTPW), specialists in developing and marketing medicines for infectiou
Source: yahoo.com
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
To lead U.S. commercial relaunch of ARAKODA® for malaria preventionWill support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON,...
Source: marketscreener.com
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
WASHINGTON, Jan. 16, 2024 -- 60 Degrees Pharmaceuticals, Inc. , a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it...
Source: marketscreener.com
Pasithea Therapeutics Announces FDA Acceptance of IND
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3....
Source: globenewswire.com